首页> 外文期刊>Journal of Medicinal Chemistry >Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.
【24h】

Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.

机译:三唑三嗪和三唑并嘧啶的新型双环哌嗪衍生物作为高效和选择性的腺苷A2A受体拮抗剂。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

A series of bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines was synthesized. Some of these analogues show high affinity and excellent selectivity for adenosine A(2a) receptor versus the adenosine A(1) receptor. Structure-activity-relationship (SAR) studies based on octahydropyrrolo[1,2-a]pyrazine and octahydropyrido[1,2-a]pyrazine with various capping groups are reported. Among these analogues, the most potent and selective A(2a) antagonist 26 h has a K(i) value of 0.2 nM and is 16 500-fold selective with respect to the A(1) receptor. Among a number of compounds tested, compounds 21a and 21c exhibited significantly improved metabolic stability. Compounds 21a, 21c, and 18a showed good oral efficacy in rodent catalepsy models of Parkinson's disease.
机译:合成了一系列三唑并三嗪和三唑并嘧啶的双环哌嗪衍生物。这些类似物中的一些显示出对腺苷A(2a)受体相对于腺苷A(1)受体具有高亲和力和出色的选择性。报道了基于八氢吡咯并[1,2-a]吡嗪和八氢吡咯并[1,2-a]吡嗪具有不同封端基团的结构-活性关系(SAR)研究。在这些类似物中,最有效和最具选择性的A(2a)拮抗剂26 h的K(i)值为0.2 nM,相对于A(1)受体具有16 500倍的选择性。在许多测试的化合物中,化合物21a和21c表现出明显改善的代谢稳定性。化合物21a,21c和18a在帕金森氏病的啮齿动物僵住症模型中显示出良好的口服功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号